What’s new in 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice?

Česká verzia

Authors: Jana Obrová ¹; Pavla Jadrníčková ²; Jan Václavík ^2,3
Authors place of work: I. interní klinika–, kardiologická, Fakultní nemocnice Olomouc ¹; Interní a kardiologická klinika, Fakultní nemocnice Ostrava ²; Katedra interních oborů, Lékařská fakulta Ostravské Univerzity ³
Published in the journal: Vnitř Lék 2022; 68(5): 295-302
Category: Review Articles
doi: https://doi.org/10.36290/vnl.2022.063

Summary

2021 ESC Guidelines on cardiovascular disease prevention in clinical practice provides a comprehensive view on preventive cardiology. It presents strategies to reduce the burden of atherosclerotic cardiovascular disease (CVD), both at the individual level and at the population level. Healthy lifestyle and aggressive control of cardiovascular risk factors remain the cornerstone of prevention. Classification of individuals into risk groups based on their clinical characteristics followed by a stepwise treatment-intensification is a novel recommended approach. Updated risk charts – SCORE2 and SCORE2-OP - are intended for estimation of 10-year fatal and non-fatal CVD risk in apparently healthy individuals. Targets and goals for LDL cholesterol, blood pressure, and glycaemic control remain as recommended in recent ESC Guidelines.

Keywords:

prevention – cardiovascular risk factors – atherosclerotic cardiovascular disease – healthy lifestyle – SCORE2 and SCORE2-OP

Zdroje

1. Visseren FLJ, Mach F, Smulders YM et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi:10.1093/eurheartj/ehab484

2. Vrablík M, Cífková R, Tuka V, Linhart A. Doporučený postup Evropské kardiologické společnosti pro prevenci kardiovaskulárních onemocnění v klinické praxi 2021. Souhrn dokumentu připravený Českou kardiologickou společností. Cor Vasa 2022;64:165–211.

3. Cosentino F, Grant PJ, Aboyans V et al. 2019 ESC Guidelines on diabetes, pre‑diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486.

4. Mach F, Baigent C, Catapano AL et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455.

5. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. doi:10.1093/eurheartj/ehy339.